Key result
Novel oral anticoagulants (dabigatran, rivaroxaban, and apixaban) were noninferior to warfarin for stroke prevention in phase 3 trials, with dabigatran and apixaban showing superiority.
Why the study?
Do novel oral anticoagulants (dabigatran, rivaroxaban, apixaban) provide effective stroke prevention and VTE treatment compared to warfarin?
Do novel oral anticoagulants (dabigatran, rivaroxaban, apixaban) provide effective stroke prevention and VTE treatment compared to warfarin?
Answers are grounded in this paper and cite their sources.
This review highlights that novel oral anticoagulants are effective and convenient alternatives to warfarin for stroke prevention in atrial fibrillation and VTE management.
Novel oral anticoagulants (OACs), including dabigatran etexilate, rivaroxaban, and apixaban, are available alternative anticoagulant therapy to vitamin K antagonists. The US Food and Drug Administration (FDA) has approved dabigatran, rivaroxaban, and apixaban for the treatment of appropriate patients for specific clinical indications. Therapeutic advantages of prescribing the new OACs are related to their predictable pharmacokinetic and pharmacodynamic properties. Dabigatran, rivaroxaban, and apixaban have all been shown to be noninferior to warfarin treatment for stroke prevention in respective phase 3 clinical trials; dabigatran and apixaban were shown to be superior to warfarin as preventive therapy. Dabigatran, rivaroxaban, and apixaban are all approved agents for stroke prevention in patients with nonvalvular atrial fibrillation in the United States and Europe. Among these agents, rivaroxaban is the only FDA-approved drug for the treatment of venous thromboembolism. This article reviews the major clinical trials that investigated the efficacy and safety of the new OACs and the use of these agents in special clinical situations.
No takes yet. Share an insight, caveat, or question.
Akwaa et al. (2013) conducted a review in Nonvalvular atrial fibrillation and venous thromboembolism. Novel oral anticoagulants (dabigatran, rivaroxaban, apixaban) vs. Warfarin was evaluated. Novel oral anticoagulants (dabigatran, rivaroxaban, and apixaban) were noninferior to warfarin for stroke prevention in phase 3 trials, with dabigatran and apixaban showing superiority.
Synapse has enriched 10 related papers. Consider them for comparative context: